Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 11/20 | 0.45 |
| ▸ | GSK3B | P49841 | 3/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | CLK2 | P49760 | 1/20 | 0.37 |
| ▸ | CLK3 | P49761 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.34 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27012406 | 0.88 | HRH3 (0.39) | OGAGSK3BDYRK1AMETHRH3 | |
| SCHEMBL10141528 | 0.88 | KDM5B (0.39) | OGAACHE | |
| SCHEMBL12089996 | 0.87 | ALOX15 (0.41) | OGAGSK3BDYRK1AMETCLK2 | |
| SCHEMBL26484672 | 0.85 | OGA (0.39) | OGAGSK3BDYRK1AACHE | |
| SCHEMBL14962150 | 0.84 | ACHE (0.44) | OGACLK2ACHE | |
| SCHEMBL2737310 | 0.84 | ACHE (0.47) | OGACLK2ACHE | |
| SCHEMBL13432296 | 0.83 | OGA (0.57) | OGAGSK3BDYRK1AMETCLK2 | |
| SCHEMBL10141501 | 0.83 | ACHE (0.46) | OGAACHE | |
| SCHEMBL18704881 | 0.83 | OGA (0.33) | OGAACHE | |
| SCHEMBL24513925 | 0.83 | GSK3B (0.38) | OGAGSK3BDYRK1AMETHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159540-A1 | PYRAZOLO[3,4-d]PYRIMIDIN-3-ONE DERIVATIVE AS WEE-1 INHIBITOR | PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE DERIVATIVE AS WEE-1 INHIBITOR (CN) | 2023-05-25 | — | — | US | disclosed |
| US-11542266-B1 | Substituted piperidines as BTK inhibitors | HAISCO PHARMACEUTICALS PTE. LTD. (SG) | 2023-01-03 | — | — | US | disclosed |
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159540-A1 | PYRAZOLO[3,4-d]PYRIMIDIN-3-ONE DERIVATIVE AS WEE-1 INHIBITOR | WEE1, WEE2, PEAK1 | OGA 4725/4885GSK3B 1803/4885DYRK1A 2370/4885 |
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MARK3, MAPK8, CDK8 | OGA 3716/4885GSK3B 138/4885DYRK1A 332/4885 |
| US-11542266-B1 | Substituted piperidines as BTK inhibitors | BTK, BLK, SYK | OGA 1689/4885GSK3B 1218/4885DYRK1A 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.